Pharmafile Logo
Pharmafocus logo
Advanced Search

Biocon

Showing 7 posts of 22 posts found.

Herceptin

Herceptin faces UK competition within months

April 11, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biocon, Herceptin, Hospira, Perjeta, breast cancer

Roche’s blockbuster breast cancer drug Herceptin may soon be under threat from copycat treatments after a court in the UK …

News
Biocon image

Novartis sues Biocon

April 4, 2014
Sales and Marketing Biocon, Galvus, Gilead, Herceptin, Novartis, sofosbuvir

India’s status as a battleground for patent issues has been reinforced with the news that Novartis is suing Biocon over …

News
herceptin_roche_cancer

India court grants Herceptin injunction

February 10, 2014
Research and Development, Sales and Marketing Biocon, Herceptin, India, Mylan, Roche

Roche has been granted an injunction by a court in India to prevent generic manufacturers of its ageing breast cancer …

News
Biocon image

Herceptin biosimilar set for Indian market

January 21, 2014
Research and Development, Sales and Marketing Biocon, Herceptin, Roche, biosimilars, canmab

Biocon has said its generic version of Roche’s ageing breast cancer drug Herceptin will go on sale in India from …

News
Roche building

Roche abandons Herceptin patents in India

August 19, 2013
Medical Communications, Sales and Marketing Biocon, GSK, Herceptin, India, Nexavar, Roche, biosimilar

News
Lantus image

Insulin blockbusters targeted by biosimilar blitz

February 15, 2013
Research and Development, Sales and Marketing Biocon, Humalog, Mylan, insulin

Mylan and Biocon are the latest companies to announce major new plans to develop and market biosimilars. The firms are …

News
Pfizer picture

Pfizer pulls out of $350 million insulin pact

March 14, 2012
Research and Development, Sales and Marketing Biocon, Humalog, Lantus, NovoLog, Pfizer

Pfizer has walked away from a research deal with India’s biggest biotech firm Biocon. Both companies were working on a …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026